Stem Cell Therapy for the Hip: Osteoarthritis & Avascular Necrosis

If your knee gets most of the attention in regenerative-medicine marketing, the hip is the joint patients ask about second — and it behaves very differently. Two conditions dominate: hip osteoarthritis and avascular necrosis (AVN) of the femoral head. Here is what the evidence actually shows for stem cell therapy in each, and what to weigh before traveling to Colombia.

Hip osteoarthritis vs. avascular necrosis

Hip osteoarthritis is wear-and-tear breakdown of the cartilage that cushions the ball-and-socket joint. It usually develops slowly with age, causing groin pain, stiffness, and reduced range of motion.

Avascular necrosis (AVN) — also called osteonecrosis of the femoral head (ONFH) — is different and often affects younger people. It happens when blood supply to the bone is interrupted, so bone tissue dies and the femoral head can eventually collapse. Causes include long-term steroid use, heavy alcohol use, trauma, and certain blood disorders. AVN is stage-dependent: caught early (before collapse), the hip can often be preserved; once the head collapses, joint replacement is usually the path.

What the research shows

Stem cells for AVN: the strongest case

The best-studied use of stem cells in the hip is for early-stage avascular necrosis combined with core decompression — a hip-preserving procedure that drills channels into the necrotic bone to relieve pressure and encourage new blood vessels. Stem cells (often bone-marrow-derived) are then implanted into that channel.

A systematic review and meta-analysis pooling 11 randomized controlled trials and 7 retrospective studies — more than 900 patients and roughly 1,250 hips — found that adding stem cells to core decompression improved hip-function scores, reduced the necrotic area, lowered the rate of femoral-head collapse, and reduced conversion to total hip replacement compared with core decompression alone. A separate meta-analysis of autologous bone-marrow stem cells reached similar conclusions for early-stage disease.

Stem cells for hip osteoarthritis

For hip OA, the data is thinner than for the knee. Most studies are smaller, and image-guided injection into the hip is technically harder than into the knee. Some patients report pain relief and improved function, but high-quality trials are limited. For advanced, bone-on-bone hip arthritis, total hip replacement remains the gold-standard treatment with decades of strong outcomes.

Cost and clinics in Colombia

Orthopedic and joint protocols in Colombia generally run $2,850–$8,500, a fraction of comparable US pricing. Clinics in Medellín (BioXcellerator, Stem Cells Colombia, LivCells), Bogotá (Stemwell, MatrixCell), and Pereira (Alevy, Regencord) offer orthopedic regenerative protocols. Some use the patient's own bone marrow or fat; others use donor umbilical-cord cells. Imaging (MRI/X-ray) to confirm staging is essential before any procedure.

Are you a candidate?

You may be a reasonable candidate to explore regenerative options if you have early-stage AVN confirmed on MRI (before collapse), mild-to-moderate hip OA, or you are trying to delay replacement and understand the evidence is incomplete. You are likely not a good candidate if the femoral head has already collapsed or you have end-stage bone-on-bone arthritis — in those cases a surgical opinion comes first.